TRIM29 can target NLRP6 and NLRP9b to modulate intestinal inflammation (Wang et al., 2024b), mitigate viral myocarditis by attenuating PERK-driven ER stress (Wang et al., 2024a), and negatively regulate type I IFN responses to RNA viruses (Xing et al., 2018). This evidence concerns the gene NLRP6 and viral myocarditis.